Prot# ML 18527: Opn-Lbl, Single Arm Study of Capecitabine (Xeloda) in Combination w/ Bevacizumab (Avastin) as First-Line Treatment for HER2-Negative Metastatic Breast Cancer, Followed by Chemotherapy in Combination w/ Bevacizumab at Time of

Project: Research project

Project Details

Effective start/end date1/11/064/1/12


  • INC Research, LLC (ML 18527 // ML 18527)
  • Roche Laboratories Inc. (ML 18527 // ML 18527)